- Home
- DYAI vs IGC Comparison
DYAI vs IGC Comparison
Compare DYAI & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- IGC
- Stock Information
- Founded
- DYAI 1979
- IGC 2005
- Country
- DYAI United States
- IGC United States
- Employees
- DYAI N/A
- IGC N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- DYAI Health Care
- IGC Health Care
- Exchange
- DYAI Nasdaq
- IGC Nasdaq
- Market Cap
- DYAI 30.2M
- IGC 33.5M
- IPO Year
- DYAI 2004
- IGC N/A
- Fundamental
- Price
- DYAI $0.85
- IGC $0.35
- Analyst Decision
- DYAI Strong Buy
- IGC Strong Buy
- Analyst Count
- DYAI 1
- IGC 2
- Target Price
- DYAI $6.00
- IGC $3.88
- AVG Volume (30 Days)
- DYAI 233.6K
- IGC 1.0M
- Earning Date
- DYAI 08-13-2025
- IGC 08-22-2025
- Dividend Yield
- DYAI N/A
- IGC N/A
- EPS Growth
- DYAI N/A
- IGC N/A
- EPS
- DYAI N/A
- IGC N/A
- Revenue
- DYAI $3,554,344.00
- IGC $1,271,000.00
- Revenue This Year
- DYAI $22.56
- IGC $15.26
- Revenue Next Year
- DYAI $30.95
- IGC $3.41
- P/E Ratio
- DYAI N/A
- IGC N/A
- Revenue Growth
- DYAI 57.59
- IGC N/A
- 52 Week Low
- DYAI $0.77
- IGC $0.25
- 52 Week High
- DYAI $2.20
- IGC $0.48
- Technical
- Relative Strength Index (RSI)
- DYAI 35.69
- IGC 48.58
- Support Level
- DYAI $0.77
- IGC $0.35
- Resistance Level
- DYAI $0.98
- IGC $0.37
- Average True Range (ATR)
- DYAI 0.09
- IGC 0.02
- MACD
- DYAI -0.03
- IGC -0.00
- Stochastic Oscillator
- DYAI 15.09
- IGC 21.86
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.